A possible reason for the side effects of Acomplia slimming pills has been discovered
Acomplia slimming pills has been associated with psychiatric side effects and now researchers think they may know why. There is a receptor in the brain known as TRPV1, which is involved in memory and learning. It is now thought that large doses of Acomplia slimming pills may block this receptor, giving rise to “suicidal thoughts” or anxiety.

In experiments in rats, it was found that the TRPV1 receptors control long term depression. Depression and memory are thought to be related. It is known that Acomplia slimming pills blocks the CB1 receptors - this is what leads to a decrease in appetite. It may be that at the correct dose level, Acomplia slimming pills does not affect the TRPV1 receptors in the brain in the majority of people. However, if in some patients the TRPV1 receptors are blocked, the hypothesis is that this could be the cause of their depression.

There are known benefits to taking Acomplia slimming pills, and this study does not address whether the benefits of taking Acomplia slimming pills outweigh the risk. Plus it is still not proven whether or not Acomplia slimming pills does actually cause mood disorders.

The FDA has still not approved Acomplia slimming pills for use in the US, but it is being prescribed across the EU. Presumably the FDA will be able to look at the European data to decide whether or not the benefits of taking Acomplia slimming pills outweigh the risks, when deciding whether or not to approve Acomplia slimming pills for the US market.

Contraindications on Acomplia slimming pills slimming pills
Acomplia slimming pills should not be taken, or should be taken only under exceptional circumstances under your doctor’s direct guidance, in the following circumstances:

Anyone who exhibits hypersensitivity or an allergic reaction to the medication (it should never be used in these circumstances).
Anyone with an impaired liver function. The effects of Acomplia slimming pills have not been studied in patients with liver damage.
Anyone with impaired kidney function. It should never be used in patients with a severly limited kidney function.
Anyone over the age of 75. There is no data currently available to establish safety in this age group.
Any children under the age of 18 - there is currently a lack of data on efficacy and safety for this age group.
Pregnant or lactating women - safety in these groups has not been established. Indeed, current data in rats shows possible damage to the developing foetus and an inhibited sucking reflex in young rats.
There is little data on the safety of Acomplia slimming pills in patients suffering from epilepsy and it should be prescribed with caution in these instances.
The Acomplia slimming pills tablet contains lactose and should therefore not be prescribed to patients with a lactose intolerance.
It should only be used with caution in combination with CYP3A4 inhibitors, such as ketocinazole, ritonavir, clarthromycin and related medications.
It should not be prescribed to patients with an uncontrolled psychiatric condition, and is not recommended for use with antidepressants as there is a lack of data on the safety in these circumstances. Acomplia slimming pills may bring about an increased incidence of “suicidal thoughts” and is not recommended for patients who are clinically depressed.